Translate Bio (NASDAQ:TBIO) announced its quarterly earnings results on Thursday. The company reported ($2.94) EPS for the quarter, missing the Zacks’ consensus estimate of $0.70 by ($3.64), Fidelity Earnings reports.
Shares of Translate Bio stock traded up $0.24 during midday trading on Friday, reaching $10.45. The company had a trading volume of 11,900 shares, compared to its average volume of 89,443. Translate Bio has a fifty-two week low of $9.21 and a fifty-two week high of $16.60.
In related news, Director Brian M. Jr. Gallagher acquired 269,230 shares of the business’s stock in a transaction that occurred on Monday, July 2nd. The shares were bought at an average cost of $13.00 per share, with a total value of $3,499,990.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Mrl Ventures Fund Llc acquired 25,000 shares of the business’s stock in a transaction that occurred on Monday, July 2nd. The stock was bought at an average cost of $13.00 per share, for a total transaction of $325,000.00. The disclosure for this purchase can be found here. 1.90% of the stock is owned by insiders.
Translate Bio Company Profile
Translate Bio, Inc, a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency.
Recommended Story: What does earnings per share mean?
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.